Alessio Beverina
Co-Founder & General Partner @ Panakes Partners
Milan, Italy
Alessio Beverina is a Series B investor at Panakes Partners in Milan focused on Medical and Health Care. Alessio Beverina is based out of Milan, Lombardia and is the Co-Founder & General Partner of Panakes Partners. Alessio previously worked at Sofinnova Partners as a Venture Partner. Alessio Beverina attended the ESCP Business School.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Alessio Beverina invests in
Stages Alessio Beverina invests in
Countries Alessio Beverina invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Series A
- $11M–$25M
- Series B
- $11M–$75M
Investment Focus
Industry
- Medical 4 (40%)
- Health Care 4 (40%)
- Medical Device 4 (40%)
- Biotechnology 2 (20%)
- SaaS 1 (10%)
Stage
- Series B 4 (40%)
- Series A 2 (20%)
- Seed 1 (10%)
- Series C 1 (10%)
- Venture - Series Unknown 1 (10%)
Country
- Italy 3 (30%)
- France 1 (10%)
- Ireland 1 (10%)
- Switzerland 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Relief provides a solution that is uni-sex, easy to use, minimally invasive, fast to insert or remove, and invisible. Their services include urinary incontinence, artificial sphincters, innovative solutions, and medical devices. | $1.1M / Venture - Series Unknown / Mar 05, 2025 | ||
| Lymphatica Medtech is a medical device development company developing a minimally invasive solution for chronic lymphedema.Lymphedema is the chronic swelling that generally occurs in the arms or the legs.Lymphedema is most commonly caused by the removal of or the damage to the lymph nodes as a part of cancer treatment. It results from ablockage in the lymphatic system, which is part of the immune system. The blockage prevents the lymphatic system from draining excess fluids, and the fluid buildup leads to swelling, infections, and pain.Unfortunately, there is no cure for lymphedema. It can be managed with early diagnosis and diligent care of the affected limb, through daily compression, bandages, and manual drainage sessions. From the moment of the diagnosis, the life of lymphedema patients changes forever.Cancer and cancer-related interventions (i.e. surgery, radiotherapy) are frequent causes of lymphedema occurring both in the upper and lower limbs. Breast cancer survivors are at high risk for developing lymphedema, as well as patients treated for melanoma, pelvic and head and neck cancer or other cancer treatments that require lymph node dissection. Physical trauma can also result in lymphedema, a major cause of lymphatic disease among wounded veterans.Lymphedema is associated with significantly impaired quality of life, skin changes, increased risk of infection and in rare cases lymphedema itself may undergo malignant transformation.Lymphatica offers a permanent solution that will allow patients to regain their normal lifestyle. | $19.6M / Series B / Oct 08, 2024 | ||
| We believe that all patients deserve the most innovative, open surgical treatment options so they can live their fullest lives. We’re on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. TheSymani® Surgical System is a first-of-its kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery to restore quality of life for more patients. | $110M / Series C / Feb 21, 2024 | ||
| Neuromod is a medical device company formed to advance the science of bi-modal neuromodulation.We are committed to delivering treatments that significantly reduce the suffering of underserved patient populations who live with chronic and debilitating conditions globally. Our goal is to design products that empower patients to take control oftheir own treatment, delivering targeted therapies that integrate seamlessly into a modern lifestyle.Neuromod has developed and patented a bi-modal neuromodulation technology that it is evaluating for neurological disorders including chronic tinnitus, a condition affecting 10% of the adult population and commonly known as 'ringing in the ears'. | $16.6M / Series B / Apr 13, 2023 | ||
| Aryel is a SaaS marketing platform that helps brands and creative agencies to easily launch engaging WebAR marketing campaigns via drag and drop, publish them through a simple custom URL, measure goals and conversions, and connect the campaign with the most used marketing tools. | $3.2M / Seed / Feb 13, 2023 | ||
| We believe that all patients deserve the most innovative, open surgical treatment options so they can live their fullest lives. We’re on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. TheSymani® Surgical System is a first-of-its kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery to restore quality of life for more patients. | $75M / Series B / Jul 20, 2022 | ||
| We believe that all patients deserve the most innovative, open surgical treatment options so they can live their fullest lives. We’re on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. TheSymani® Surgical System is a first-of-its kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery to restore quality of life for more patients. | $24.8M / Series A / Apr 18, 2018 | ||
| Aledia develops and manufactures innovative light-emitting diodes based on a unique 3D architecture using gallium-nitride on-silicon microwires.The technology uses standard silicon wafers with diameters of 8 inches (200 mm) and existing CMOS wafer-fabrication processes and tools, enabling the production of LED chips at 25 percent of the cost oftraditional planar LED chips. The process and tools help develop both mobile displays and microdisplays for AR/VR applications, enabling users to use them for direct-view displays such as for smartphones, smartwatches, tablets, and laptops. In 2011, Giorgio Anania, Philippe Gilet, and Xavier Hugon co-founded the Grenoble, Rhone-Alpes-based company. | $31M / Series B / Jun 18, 2015 | ||
| Aledia develops and manufactures innovative light-emitting diodes based on a unique 3D architecture using gallium-nitride on-silicon microwires.The technology uses standard silicon wafers with diameters of 8 inches (200 mm) and existing CMOS wafer-fabrication processes and tools, enabling the production of LED chips at 25 percent of the cost oftraditional planar LED chips. The process and tools help develop both mobile displays and microdisplays for AR/VR applications, enabling users to use them for direct-view displays such as for smartphones, smartwatches, tablets, and laptops. In 2011, Giorgio Anania, Philippe Gilet, and Xavier Hugon co-founded the Grenoble, Rhone-Alpes-based company. | $11M / Series A / Apr 03, 2013 | ||
| Neuromod is a medical device company formed to advance the science of bi-modal neuromodulation.We are committed to delivering treatments that significantly reduce the suffering of underserved patient populations who live with chronic and debilitating conditions globally. Our goal is to design products that empower patients to take control oftheir own treatment, delivering targeted therapies that integrate seamlessly into a modern lifestyle.Neuromod has developed and patented a bi-modal neuromodulation technology that it is evaluating for neurological disorders including chronic tinnitus, a condition affecting 10% of the adult population and commonly known as 'ringing in the ears'. | $10.9M / Series B |
Co-Investors
About Panakes Partners
Panakès Partners is a Venture Capital firm, based in Milan, which invests in the most ambitious companies and teams, developing revolutionary technologies and products, in the field of life sciences, aiming to improve the lives of people around the world. Panakès, founded in 2015 by Fabrizio Landi, Alessio Beverina and Diana Saraceni, has 250million under management.
Panakes Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Alessio Beverina
Co-Founder & General Partner
|
|||
Fabrizio Landi
Founder and Managing Partner
|
|||
Barbara Castellano
Partner
|
|||
Diana Saraceni
General partner
|
|||
Rob Woodman
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Alessio Beverina invest in?
Alessio Beverina invests primarily in Medical, Health Care and Medical Device startups, most often at Series B and Series A stage. Most of the 10 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Alessio Beverina's check size?
Alessio Beverina typically joins rounds of $11M–$25M at Series A and $11M–$75M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Alessio Beverina participates in.
How do I contact Alessio Beverina?
Public channels for Alessio Beverina include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Alessio Beverina last invest?
The most recent investment recorded for Alessio Beverina closed in Mar 2025. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
